FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2330753947> ?p ?o ?g. }

• W2330753947 endingPage "671" @default.
• W2330753947 startingPage "671.6" @default.
• W2330753947 abstract "<h3>Background</h3> Tocilizumab (TCZ) is a humanized anti-interleukin 6 receptor (IL-6R) monoclonal antibody and it was approved in Japan as an antirheumatic drugs in 2008. Evidence of the efficacy of TCZ in real-world RA patients is still few as compared with tumour necrosis factor (TNF) inhibitors. <h3>Objectives</h3> We have tried to evaluate the efficacy of TCZ in patients with RA during the 3 years after an approval in 2008 at Nagasaki prefecture, Japan. <h3>Methods</h3> One hundred fifty-two RA patients at Nagasaki prefecture, Japan, who has received 8 mg/kg of TCZ every 4 weeks during 3 years, were consecutively enrolled in this study. Ninety-nine patients had evaluable data for 1 year at present. We have focused on the efficacy of TCZ in the present study trying to evaluate the clinical response of disease activity score (DAS) 28, simplified disease activity index (SDAI), clinical disease activity index (CDAI), Boolean approach and Health Assessment Questionnaire (HAQ) by last observation carried forward (LOCF) methodology toward these 99 patients, respectively. <h3>Results</h3> The mean age, disease duration and clinical disease activity at baseline were 58 years-old, 11 years, DAS28-ESR: 5.5, SDAI: 28.7 and CDAI: 25.5, respectively. Fifty-nine percent of the patients had received TNF inhibitors before introduction of TCZ. Although most of the patients were active as well as established disease at baseline, the continuation rate at 1 year was superior as 81.1%. A rate of clinical remission at 1 year of DAS28-ESR, SDAI, CDAI and Boolean-based definition was 49.5%, 17.2%, 13.1% and 13.1%, respectively. There was a clear relation of the rate of clinical remission with shorter disease duration (less than 2 years) or no previous history of TNF inhibitors. Furthermore, low HAQ at baseline was the only variable to be associated with CDAI remission (OR [95% CI]: 0.34 [0.09-0.88], p=0.06) and HAQ remission (OR [95% CI]: 0.17 [0.03-0.50], p<0.01) at 1 year defined by logistic regression analysis. <h3>Conclusions</h3> The present study shows an excellent therapeutic efficacy as well as the characterisitic of patients being achieved in remission by TCZ in the real-world clinical practice. <h3>References</h3> Kawashiri SY, et al. In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline. Mod Rheumatol. 2011;21:370-4. Kawashiri SY, et al. Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index. Mod Rheumatol. 2011;21:365-9. <h3>Disclosure of Interest</h3> None Declared" @default.
• W2330753947 created "2016-06-24" @default.
• W2330753947 creator A5000556430 @default.
• W2330753947 creator A5013815950 @default.
• W2330753947 creator A5039922819 @default.
• W2330753947 creator A5044442302 @default.
• W2330753947 creator A5057574490 @default.
• W2330753947 creator A5070326257 @default.
• W2330753947 creator A5074758212 @default.
• W2330753947 creator A5082577947 @default.
• W2330753947 creator A5084299259 @default.
• W2330753947 creator A5087056355 @default.
• W2330753947 creator A5091177614 @default.
• W2330753947 date "2013-06-01" @default.
• W2330753947 modified "2023-09-26" @default.
• W2330753947 title "AB0574 Evaluation of the efficacy of tocilizumab toward the patients with active rheumatoid arthritis of nagasaki prefecture, japan" @default.
• W2330753947 doi "https://doi.org/10.1136/annrheumdis-2012-eular.574" @default.
• W2330753947 hasPublicationYear "2013" @default.
• W2330753947 type Work @default.
• W2330753947 sameAs 2330753947 @default.
• W2330753947 citedByCount "1" @default.
• W2330753947 countsByYear W23307539472018 @default.
• W2330753947 crossrefType "journal-article" @default.
• W2330753947 hasAuthorship W2330753947A5000556430 @default.
• W2330753947 hasAuthorship W2330753947A5013815950 @default.
• W2330753947 hasAuthorship W2330753947A5039922819 @default.
• W2330753947 hasAuthorship W2330753947A5044442302 @default.
• W2330753947 hasAuthorship W2330753947A5057574490 @default.
• W2330753947 hasAuthorship W2330753947A5070326257 @default.
• W2330753947 hasAuthorship W2330753947A5074758212 @default.
• W2330753947 hasAuthorship W2330753947A5082577947 @default.
• W2330753947 hasAuthorship W2330753947A5084299259 @default.
• W2330753947 hasAuthorship W2330753947A5087056355 @default.
• W2330753947 hasAuthorship W2330753947A5091177614 @default.
• W2330753947 hasConcept C126322002 @default.
• W2330753947 hasConcept C2777178219 @default.
• W2330753947 hasConcept C2777575956 @default.
• W2330753947 hasConcept C2908564923 @default.
• W2330753947 hasConcept C2909063479 @default.
• W2330753947 hasConcept C71924100 @default.
• W2330753947 hasConceptScore W2330753947C126322002 @default.
• W2330753947 hasConceptScore W2330753947C2777178219 @default.
• W2330753947 hasConceptScore W2330753947C2777575956 @default.
• W2330753947 hasConceptScore W2330753947C2908564923 @default.
• W2330753947 hasConceptScore W2330753947C2909063479 @default.
• W2330753947 hasConceptScore W2330753947C71924100 @default.
• W2330753947 hasIssue "Suppl 3" @default.
• W2330753947 hasLocation W23307539471 @default.
• W2330753947 hasOpenAccess W2330753947 @default.
• W2330753947 hasPrimaryLocation W23307539471 @default.
• W2330753947 hasRelatedWork W189077404 @default.
• W2330753947 hasRelatedWork W1979392798 @default.
• W2330753947 hasRelatedWork W2355352419 @default.
• W2330753947 hasRelatedWork W2794029630 @default.
• W2330753947 hasRelatedWork W2953955431 @default.
• W2330753947 hasRelatedWork W2996380604 @default.
• W2330753947 hasRelatedWork W3014745169 @default.
• W2330753947 hasRelatedWork W3024842914 @default.
• W2330753947 hasRelatedWork W4239841759 @default.
• W2330753947 hasRelatedWork W4254827893 @default.
• W2330753947 hasVolume "71" @default.
• W2330753947 isParatext "false" @default.
• W2330753947 isRetracted "false" @default.
• W2330753947 magId "2330753947" @default.
• W2330753947 workType "article" @default.